Moderna Reports Q1 2025 Financial Results Highlighting Strategic Adjustments

Moderna, Inc. has revealed its first-quarter results for 2025, reporting revenues of $0.1 billion and a GAAP net loss of $1.0 billion, translating to a loss per share of $2.52. Despite this, the firm maintains its projected year-end cash balance at approximately $6 billion and anticipates annual revenues between $1.5 and $2.5 billion for 2025.

The company is actively working on reducing its operating costs, aiming for a cost reduction of $1.4 to $1.7 billion by 2027. Significant focus is being placed on advancing up to 10 products towards approval, including key oncology candidates.

Commercially, Moderna reported $84 million in Spikevax® sales in Q1 2025 and achieved $2 million from its RSV vaccine, newly approved in four countries. The company’s cash and investment reserves stand at $8.4 billion, while it continues to streamline operations, reflected in decreased research and administrative expenses.